JPWO2020022507A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020022507A5
JPWO2020022507A5 JP2020532517A JP2020532517A JPWO2020022507A5 JP WO2020022507 A5 JPWO2020022507 A5 JP WO2020022507A5 JP 2020532517 A JP2020532517 A JP 2020532517A JP 2020532517 A JP2020532517 A JP 2020532517A JP WO2020022507 A5 JPWO2020022507 A5 JP WO2020022507A5
Authority
JP
Japan
Prior art keywords
benzyloxyphenylthio
chlorophenyl
diol
propane
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020532517A
Other languages
English (en)
Japanese (ja)
Other versions
JP7389486B2 (ja
JPWO2020022507A1 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2019/029524 external-priority patent/WO2020022507A1/ja
Publication of JPWO2020022507A1 publication Critical patent/JPWO2020022507A1/ja
Publication of JPWO2020022507A5 publication Critical patent/JPWO2020022507A5/ja
Application granted granted Critical
Publication of JP7389486B2 publication Critical patent/JP7389486B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020532517A 2018-07-27 2019-07-26 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤 Active JP7389486B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2018141411 2018-07-27
JP2018141411 2018-07-27
JP2019036598 2019-02-28
JP2019036598 2019-02-28
PCT/JP2019/029524 WO2020022507A1 (ja) 2018-07-27 2019-07-26 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤

Publications (3)

Publication Number Publication Date
JPWO2020022507A1 JPWO2020022507A1 (ja) 2021-08-05
JPWO2020022507A5 true JPWO2020022507A5 (https=) 2022-07-28
JP7389486B2 JP7389486B2 (ja) 2023-11-30

Family

ID=69181631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020532517A Active JP7389486B2 (ja) 2018-07-27 2019-07-26 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤

Country Status (11)

Country Link
US (1) US20210283073A1 (https=)
EP (1) EP3831370A4 (https=)
JP (1) JP7389486B2 (https=)
KR (1) KR102948053B1 (https=)
CN (2) CN112512516A (https=)
AU (1) AU2019311609B2 (https=)
BR (1) BR112021001376A2 (https=)
IL (1) IL280451B2 (https=)
MX (1) MX2021001039A (https=)
TW (1) TWI899057B (https=)
WO (1) WO2020022507A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021424131A1 (en) * 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
EP4248958A3 (en) 2021-01-28 2024-01-03 Priothera SAS Methods of treatment with s1p receptor modulators
EP4282407A1 (en) 2022-05-27 2023-11-29 Priothera SAS Treatment of cancer with s1p receptor agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1431275B1 (en) 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
MXPA04002679A (es) 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
CN101014329B (zh) * 2004-07-16 2010-09-08 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
EP1806338B1 (en) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
SI1932522T1 (sl) 2005-10-07 2012-08-31 Kyorin Seiyaku Kk Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
AU2009206733A1 (en) * 2008-01-25 2009-07-30 Arena Pharmaceuticals, Inc. Dihydro- 1H- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as S1P1 agonists
WO2014120949A1 (en) * 2013-01-30 2014-08-07 Memorial Sloan-Kettering Cancer Center Donor kir3dl1 and hla-b subtypes and leukemia control in hla-compatible allogenic hematopoietic stem cell transplantation
US20160000811A1 (en) * 2013-02-20 2016-01-07 Novartis Ag Treatment of graft versus host disease in transplant patients
US10154989B2 (en) * 2015-09-17 2018-12-18 Emory University Methods of managing graft versus host disease (GvHD) using indole carboxyaldehydes or derivatives thereof
WO2017153889A1 (en) 2016-03-08 2017-09-14 Novartis Ag Treatment of hematopoietic stem cell transplant patients

Similar Documents

Publication Publication Date Title
JP2023041862A5 (https=)
Zorzi et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
JP2021066744A5 (ja) ブプロピオンおよびデキストロメトルファンを含む組成物
JP2009545620A5 (https=)
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
JPWO2020022507A5 (https=)
JP2019515909A5 (https=)
JP2007520506A5 (https=)
JP2019508476A5 (https=)
JP2016509050A5 (https=)
JP2019526559A5 (https=)
CN115916778A (zh) 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
JP2020529995A5 (https=)
CL2024003601A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2005508896A5 (https=)
JP2012525358A5 (https=)
JP2016505050A5 (https=)
JP2014534229A5 (https=)
TWI899057B (zh) 接受造血幹細胞移植的患者之血液惡性腫瘤的復發抑制劑
JP2019535830A5 (https=)
JPWO2017184774A5 (https=)
CN115279344A (zh) 盐酸米托蒽醌脂质体的用途
WO2004043336A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
IL275091B2 (en) Methods for treating gaucher disease
AU2017231000B2 (en) Treatment of hematopoietic stem cell transplant patients